

TheMARK

GlycoMark Updates for Healthcare Professionals
Caring for Patients with Diabetes

DIABETES MANAGEMENT

Issue 18 - May Special Edition

Dear Healthcare Professionals,



New GlycoMark® and SGLT-2 Inhibitor Clinical Data to be Presented at the ADA's 79th Scientific Sessions

"GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT2 Inhibitors"

Sunday, June 9 - 12:00 - 1:00 PM

Poster Hall (Hall F, North, Exhibition Level)

Moscone Center, San Francisco, California

Clinical Therapeutics/New Technology-SGLT Inhibitors
Poster Session (1227-P)

The GlycoMark test, which identifies recent hyperglycemia and hyperglycemic excursions, complements other tests for diabetes for a more complete assessment.

The GlycoMark leadership team will be attending the ADA - Schedule a meeting with us!

[Schedule a Meeting at ADA](#)

[Request Study Poster](#)

Don't forget to also request copies of the NEW Patient Guide and Poster/Display for your office!



GlycoMark
"Know Both Your Numbers"
Patient Guide




GlycoMark
"Know Both Your Numbers"
Poster/Display

[Request Printed Copies](#)

How to Order the GlycoMark Test:

The GlycoMark test is available through numerous national and regional laboratories, and through LabFinder. Contact your preferred laboratory for information or download the NEW [GlycoMark Test Ordering Guide](#) to identify a laboratory and corresponding test codes.



The GlycoMark Test is reimbursed by most federal, state and private payers, CPT 84378.

To order test kits for your laboratory, please refer to our [online resources](#) and [contact us!](#) We are happy to help support you in setting up the test on any open channel chemistry platform.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2019 GlycoMark, Inc. All Rights Reserved. M-83-1A



805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - info@glycomark.com - www.glycomark.com